You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

DIPRIVAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Diprivan patents expire, and what generic alternatives are available?

Diprivan is a drug marketed by Fresenius Kabi Usa and is included in one NDA. There is one patent protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in DIPRIVAN is propofol. There are twelve drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the propofol profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Diprivan

A generic version of DIPRIVAN was approved as propofol by SAGENT PHARMS INC on January 4th, 1999.

  Try a Trial

Drug patent expirations by year for DIPRIVAN
Drug Prices for DIPRIVAN

See drug prices for DIPRIVAN

Recent Clinical Trials for DIPRIVAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jenna L Leclerc MD, PhDPhase 2/Phase 3
The University of Hong KongPhase 4
Hong Kong Children's HospitalPhase 4

See all DIPRIVAN clinical trials

Pharmacology for DIPRIVAN
Drug ClassGeneral Anesthetic
Physiological EffectGeneral Anesthesia
Anatomical Therapeutic Chemical (ATC) Classes for DIPRIVAN

US Patents and Regulatory Information for DIPRIVAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa DIPRIVAN propofol INJECTABLE;INJECTION 019627-001 Oct 2, 1989 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Fresenius Kabi Usa DIPRIVAN propofol INJECTABLE;INJECTION 019627-002 Jun 11, 1996 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DIPRIVAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Fresenius Kabi Usa DIPRIVAN propofol INJECTABLE;INJECTION 019627-002 Jun 11, 1996 ⤷  Try a Trial ⤷  Try a Trial
Fresenius Kabi Usa DIPRIVAN propofol INJECTABLE;INJECTION 019627-002 Jun 11, 1996 ⤷  Try a Trial ⤷  Try a Trial
Fresenius Kabi Usa DIPRIVAN propofol INJECTABLE;INJECTION 019627-002 Jun 11, 1996 ⤷  Try a Trial ⤷  Try a Trial
Fresenius Kabi Usa DIPRIVAN propofol INJECTABLE;INJECTION 019627-002 Jun 11, 1996 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for DIPRIVAN

See the table below for patents covering DIPRIVAN around the world.

Country Patent Number Title Estimated Expiration
Finland 120640 ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 9629064 ⤷  Try a Trial
Luxembourg 90136 ⤷  Try a Trial
Spain 2183869 ⤷  Try a Trial
Denmark 0814787 ⤷  Try a Trial
Sweden 9703274 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.